Diagnostic Center | April 16, 2024
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The 200 bedded hospital owned & operated by Alexis
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The workshop was conducted as a part of the NITI–State workshop series
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
This acquisition marks Max Healthcare's entry into Lucknow
Subscribe To Our Newsletter & Stay Updated
